Sickle Cell Disease

Overview

Sickle cell disease (SCD) is an inherited disorder in which a change in the hemoglobin gene causes red blood cells to become rigid and sickle-shaped under stress. These cells can block small blood vessels, causing episodes of severe pain known as vaso-occlusive crises (VOCs), chronic anemia, infections, stroke, lung complications, and progressive damage to organs. It is lifelong and can shorten life expectancy, particularly when severe complications accumulate. Treatment options and perspective

Standard care aims to prevent complications rather than correct the underlying mutation. It includes hydroxyurea to raise protective fetal hemoglobin, vaccinations and infection prevention, pain management, transfusions or red-cell exchange when indicated, and monitoring for brain, kidney, lung, eye, and heart complications. A donor-derived hematopoietic stem-cell transplant can cure some people, but it requires a suitably matched donor and carries risks including graft-versus-host disease, infertility, and transplant-related toxicity. Treatment options and perspective

Scope of Recent Research (2020–present)

Research since 2020 has shifted SCD from a field focused mainly on symptom control toward potentially curative, one-time cellular treatments. The central questions are now how to make enough healthy or fetal hemoglobin, how to permanently modify a patient’s own blood-forming stem cells safely, how to avoid toxic preparative chemotherapy, and how to deliver these therapies equitably. The field has already produced approved gene therapies, but their long-term durability, safety, and real-world accessibility remain under active study. Cure Sickle Cell Initiative CMS Gene Therapy Access Model

Major Breakthroughs and Emerging Therapies

The first major curative strategy remains allogeneic hematopoietic stem-cell transplantation, in which donor bone-marrow stem cells replace the patient’s blood-forming system. It can eliminate SCD, but donor availability and immune complications limit its use. Recent research has increasingly used the transplant framework with a patient’s own cells—an autologous transplant—thereby avoiding rejection and graft-versus-host disease while attempting to correct the genetic cause of disease. Treatment options and perspective

The most consequential recent advance is exagamglogene autotemcel (Casgevy), an autologous CRISPR–Cas9 edited cell therapy. Scientists collect CD34-positive blood-forming stem cells, edit a regulatory region of BCL11A, and reinfuse the cells after high-intensity conditioning chemotherapy. The edit restores production of fetal hemoglobin (HbF), a form of hemoglobin that does not sickle. In the phase 3 CLIMB SCD-121 study, 29 of 30 efficacy-evaluable participants were free of severe VOCs for at least 12 consecutive months. Exagamglogene autotemcel phase 3 trial In July 2026, the U.S. Food and Drug Administration expanded Casgevy’s SCD indication to patients aged 2 years and older with recurrent VOCs; among eight efficacy-evaluable children aged 5 to under 12 years in the supporting study, all met the 12-month severe-VOC-free endpoint. FDA pediatric Casgevy approval

A second approved approach, lovotibeglogene autotemcel (Lyfgenia), uses a lentiviral vector to add a modified anti-sickling beta-globin gene to the patient’s own stem cells. Rather than editing DNA with CRISPR, it supplies cells capable of making HbA^T87Q, a modified hemoglobin designed to resist sickling. FDA’s approval analysis found that 28 of 32 patients achieved complete resolution of vaso-occlusive events between 6 and 18 months after infusion. FDA approval of first SCD gene therapies This benefit must be weighed against a boxed warning for hematologic malignancy and a requirement for long-term monitoring. Lyfgenia prescribing information

Newer editing programs seek to make HbF induction more precise or more potent. Renizgamglogene autogedtemcel (reni-cel, formerly EDIT-301) uses CRISPR–Cas12a to edit the HBG1 and HBG2 fetal-hemoglobin promoters directly, disrupting binding sites for BCL11A. In a phase 1–2 study, 27 of 28 treated participants had no VOCs after infusion at the October 2024 data cutoff, with average HbF rising to about 48% at month 6; however, the study was terminated early after the sponsor changed development priorities. Reni-cel phase 1–2 study Ristoglogene autogetemcel (risto-cel; BEAM-101) uses base editing, which changes a targeted DNA letter without creating a double-strand DNA break, to block BCL11A binding at the same fetal-hemoglobin promoters. Its phase 1–2 study represents an important test of whether base editing can deliver an effective HbF-based functional cure with a different editing profile. Risto-cel base-editing study

Other experimental approaches aim to reduce the burden of conditioning chemotherapy or directly repair the original sickle mutation. A 2025 phase 1–2 study reported transplantation of lentivirus-modified autologous stem cells after reduced-intensity conditioning, a possible route toward less toxic treatment. Reduced-intensity lentiviral gene therapy Separately, preclinical work has shown that TALEN gene editing plus a DNA repair template can precisely correct the sickle mutation in patient-derived stem cells, although this has not yet established clinical efficacy. TALEN correction of the sickle mutation

Clinical Trials and Experimental Approaches

Casgevy’s pivotal phase 3 trial enrolled adolescents and adults with severe SCD and recurrent VOCs; its high rate of prolonged VOC freedom supported the first FDA approval of a CRISPR-based medicine in December 2023. Exagamglogene autotemcel phase 3 trial Lyfgenia, sponsored by bluebird bio, was approved at the same time based on a single-arm multicenter study, while its label requires lifelong malignancy surveillance. FDA approval of first SCD gene therapies Lyfgenia prescribing information

Important active academic trials include UCSF’s phase 1–2 CRISPR_SCD001 study, which attempts to correct the sickle mutation in a patient’s own stem cells, and St. Jude’s phase 1 SAGES1 study, which is testing autologous CRISPR-edited CD34-positive cells in people aged 18 to 25 years. CRISPR-SCD trial SAGES1 trial record The BEACON phase 1–2 program has tested base-edited BEAM-101/risto-cel, while the RUBY study provided the clinical proof of concept for direct fetal-hemoglobin promoter editing with reni-cel. Risto-cel base-editing study Reni-cel phase 1–2 study

Methodologies and Scientific Approaches

Most curative studies collect autologous CD34-positive hematopoietic stem and progenitor cells by apheresis, modify the cells outside the body, and reinfuse them after chemotherapy clears space in the bone marrow. Researchers then measure engraftment, total hemoglobin, HbF, markers of red-cell destruction, editing frequency, vector integration where relevant, and clinical outcomes such as severe VOCs, hospitalizations, transfusion needs, and organ-function measures. Exagamglogene autotemcel phase 3 trial Reni-cel phase 1–2 study

The major platforms are lentiviral gene addition, CRISPR nuclease editing, base editing, and precise mutation correction with a donor DNA template. A common biological strategy is to recreate the naturally protective state of hereditary persistence of fetal hemoglobin: instead of fixing every red cell directly, researchers alter long-lived blood stem cells so their descendants continuously make high levels of HbF. Risto-cel base-editing study TALEN correction of the sickle mutation

Leading Institutions and Funding

Key drivers include Vertex Pharmaceuticals and CRISPR Therapeutics for Casgevy; bluebird bio for Lyfgenia; Editas Medicine for reni-cel; Beam Therapeutics for risto-cel/BEAM-101; and academic centers including UCSF, Boston Children’s Hospital, St. Jude Children’s Research Hospital, Stanford, and major transplant centers. The NHLBI-led Cure Sickle Cell Initiative supports development of genetic cures and multicenter clinical trials focused on modifying blood-forming stem cells. Cure Sickle Cell Initiative CRISPR-SCD trial SAGES1 trial record

The California Institute for Regenerative Medicine has made a concrete investment in this pipeline: its 2021 Cure Sickle Cell Initiative clinical-trial-stage awards totaled $17.3 million, including approximately $8.39 million for UCSF’s CRISPR_SCD001 program and approximately $8.33 million for Boston Children’s Hospital’s fetal-hemoglobin gene-transfer study. CIRM Cure Sickle Cell awards

Strengths, Limitations, and Challenges

The strongest evidence is that altering a patient’s own stem cells can produce sustained HbF or anti-sickling hemoglobin and can sharply reduce, or eliminate for extended periods, the VOCs that drive much of SCD’s acute burden. Autologous therapies also avoid the need for a matched donor and the risk of graft-versus-host disease. Exagamglogene autotemcel phase 3 trial FDA approval of first SCD gene therapies

However, approved and late-stage therapies still require complex cell collection, specialized manufacturing, prolonged hospitalization, and myeloablative conditioning, which can cause severe low blood counts, infection risk, mucositis, infertility, and other toxicities. CRISPR therapies also require continued scrutiny for unintended edits, while lentiviral gene addition requires long-term monitoring for insertion-related cancer risk. FDA pediatric Casgevy approval Lyfgenia prescribing information Cost and access are equally consequential: U.S. prices have been estimated at roughly $2 million to $3 million per treatment, and the affected population is disproportionately Black and often covered by Medicaid, prompting the CMS Cell and Gene Therapy Access Model. CMS Gene Therapy Access Model

Outlook and Future Directions

SCD now has credible, clinically validated routes to a functional cure for selected patients, and Casgevy’s expansion to children as young as 2 years marks a major step toward earlier intervention. FDA pediatric Casgevy approval The next milestones are long-term follow-up confirming durable benefit and safety, safer non-genotoxic conditioning or conditioning-free transplantation, reliable direct correction of HBB, scalable manufacturing, and payment and care models that make curative treatment available beyond a small number of specialized centers. Reduced-intensity lentiviral gene therapy CMS Gene Therapy Access Model

References

• Treatment options and perspective — Frontiers in Medicine, 2023.
• Exagamglogene autotemcel phase 3 trial — Frangoul et al., 2024.
• FDA approval of first SCD gene therapies — U.S. Food and Drug Administration, 2023.
• Lyfgenia prescribing information — U.S. Food and Drug Administration, 2023.
• FDA pediatric Casgevy approval — U.S. Food and Drug Administration, 2026.
• Reni-cel phase 1–2 study — Hanna et al., 2026.
• Risto-cel base-editing study — Heeney et al., 2026.
• Reduced-intensity lentiviral gene therapy — Nature Medicine, 2025.
• TALEN correction of the sickle mutation — Nature Communications, 2024.
• CRISPR-SCD trial — Cure Sickle Cell Initiative, 2026.
• SAGES1 trial record — ClinicalTrials.gov, 2026.
• Cure Sickle Cell Initiative — National Heart, Lung, and Blood Institute, 2026.
• CIRM Cure Sickle Cell awards — California Institute for Regenerative Medicine, 2021.
• CMS Gene Therapy Access Model — Ballreich, Odouard, and Socal, 2025.